clinical trial · NCT04695327
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy
Solid TumorTILT-123
brief summary
This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.
started
Jan 11, 2021
primary completion
Sep 3, 2025
completion
Sep 3, 2025
last updated
Mar 6, 2026
detailed description
This is an open-label, phase 1, dose-escalation trial evaluating the safety of TILT-123 as monotherapy in advanced solid tumor patients. TILT-123 is an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin 2. The trial includes 2 healthcare centers in Helsinki (Finland). Patients with different indications are expected to be treated in the trial.
official title
A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol